Skip to main content
. Author manuscript; available in PMC: 2019 Nov 29.
Published in final edited form as: Nature. 2019 May 29;570(7762):468–473. doi: 10.1038/s41586-019-1250-z

Extended Data Fig. 1. RC1 characterization.

Extended Data Fig. 1.

a, Comparison of geometric mean IC50 values for V3-glycan patch bNAbs (10–1074 and PGT121) and a N156 glycan-dependent V1V2 bNAb (BG1) evaluated against HIV-1 strains either containing or not containing a PNGS at the indicated positions (number of HIV-1 strains indicated in the parentheses). IC50values > 50 μg/mL set to 50 μg/mL for geometric mean calculations. Whereas V3-glycan patch bNAbs show enhanced neutralization upon removal of the N156 glycan, removal of nearby glycans (N137, N301) diminished or had little effect on neutralization. b, Graphs of ELISA data showing binding of different classes of bNAbs to RC1, RC1–4fill, and BG505. bNAbs were evaluated at 5μg/ml and seven additional 3-fold dilutions.n=2. RC1 and RC1-fill show similar binding patterns for V3-glycan patch bNAbs, CD4-binding site bNAbs (CD4bs), gp120-gp41 interface bNAbs, but not to BG1, a V1V2 bNAb that interacts with the N156 glycan (see panel a).